TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32711612
Drug: NAB PC
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: NAB PC (albumin‐binding paclitaxel 130 mg/mL, D1, D; carboplatin AUC = 6, D1)
Study: 32711612
Drug: PC (paclitaxel
Approvals — FDA: no, EMA: no, PMDA: no
Description: PC (paclitaxel 175 mg/mL, D1; carboplatin AUC = 6, D1)
Study: 32950674
Drug: Corticosteroid Injection
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid Injection (CS)
Study: 36053506
Drug: Bedaquiline-Pretomanid-Linezolid with
Normalized name: pretomanid
DrugBank: Pretomanid (DB05154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bedaquiline-Pretomanid-Linezolid with linezolid at a dose of 1200 mg for 26 weeks
Study: 36053506
Drug: Bedaquiline-Pretomanid-Linezolid with
Normalized name: pretomanid
DrugBank: Pretomanid (DB05154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bedaquiline-Pretomanid-Linezolid with linezolid at a dose of 1200 mg for 9 weeks
Study: 36053506
Drug: Bedaquiline-Pretomanid-Linezolid with
Normalized name: pretomanid
DrugBank: Pretomanid (DB05154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bedaquiline-Pretomanid-Linezolid with linezolid at a dose of 600 mg for 26 weeks
Study: 36053506
Drug: Bedaquiline-Pretomanid-Linezolid with
Normalized name: pretomanid
DrugBank: Pretomanid (DB05154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bedaquiline-Pretomanid-Linezolid with linezolid at a dose of 600 mg for 9 weeks
Study: 34023009
Drug: Upadacitinib 15
Normalized name: upadacitinib 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upadacitinib 15 mg plus topical corticosteroids
Study: 34023009
Drug: Upadacitinib 30
Normalized name: upadacitinib 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upadacitinib 30 mg plus topical corticosteroids
Study: 35665810
Drug: GAD-alum (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: GAD-alum (4 μg) with oral vitamin D
Study: 35940560
Drug: Topical tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical tranexamic acid (TXA) and Placebo
Study: 33844449
Drug: Atorvastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (40 mg once daily)
Study: 35972165
Drug: Preoperative 8-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative 8-mg dexamethasone
Study: 32506738
Drug: Maribavir 100
Normalized name: MARIBAVIR
DrugBank: Maribavir (DB06234)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Maribavir 100 mg
Study: 32506738
Drug: Maribavir 1200
Normalized name: MARIBAVIR
DrugBank: Maribavir (DB06234)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Maribavir 1200 mg
Study: 32506738
Drug: Maribavir (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maribavir (both doses)
Study: 32517564
Drug: Rape myth
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rape myth intervention (treatment group)
Study: 34814766
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment during chemotherapy
Study: 38488975
Drug: Guselkumab 100
Normalized name: guselkumab 100 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guselkumab 100 mg every 4 weeks (Q4W)
Study: 38488975
Drug: Guselkumab 100
Normalized name: guselkumab 100 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guselkumab 100 mg every 8 weeks (Q8W)
Study: 33559434
Drug: Acupotomy combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupotomy combined with Xingnao Kaiqiao acupuncture therapy
Study: 33559434
Drug: Xingnao Kaiqiao
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xingnao Kaiqiao acupuncture therapy
Study: 35970518
Drug: Fluticasone furoate/violanterol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone furoate/violanterol (FF/VI) 100/25 μg
Study: 34727465
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg Dexamethasone (DXM)
Study: 32062847
Drug: Administered chemoprophylaxis
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered chemoprophylaxis
Study: 32062847
Drug: Post-operative VTE
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-operative VTE dosing
Study: 32332670
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy at a wavelength of 808 nm, administered twice per week for a total of 12 sessions.
Study: 32332670
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment (simulated laser therapy), administered twice per week for a total of 12 sessions.
Study: 35684041
Drug: Red orange
Normalized name: TITANIUM DIOXIDE 2.32 g in 25 g CUTANEOUS CREAM [RED ORANGE JELLY BB SPF20 PA PLUS PLUS NO.1]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red orange extract (100 mg/day)
Study: 35657581
Drug: CC-292 SDD
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC-292 SDD tablet under fed conditions
Study: 35657581
Drug: CC-292 SDD
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC-292 SDD tablet after multiple doses of omeprazole (40 mg)
Study: 35657581
Drug: CC-292 SDD
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC-292 SDD formulation (100–300 mg)
Study: 35657581
Drug: CC-292 under
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CC-292 under all conditions
Study: 35657581
Drug: CC-292 under
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CC-292 under fed vs fasted conditions
Study: 33328269
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg praliciguat
Study: 33328269
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg praliciguat
Study: 33451591
Drug: Gabapentin (1800-2400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (1800-2400 mg/d)
Study: 33451591
Drug: Active comparator
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active comparator (ondansetron 24-32 mg/d or metoclopramide 45-60 mg/d)
Study: 33004730
Drug: 1% Clotrimazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% Clotrimazole (antifungal)
Study: 33963971
Drug: Single intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous ascending doses of apitegromab (1, 3, 10, 20, 30 mg/kg)
Study: 33963971
Drug: Multiple intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple intravenous ascending doses of apitegromab (10, 20, 30 mg/kg)
Study: 33963971
Drug: Single and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single and multiple doses of apitegromab
Study: 33176409
Drug: Ultrasound guided
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound guided continuous lumbar plexus block (LPB) with 0.5% ropivacaine (15 mL)
Study: 33176409
Drug: Continuous epidural
Normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous epidural anesthesia (CEA) with 0.5% ropivacaine (15 mL)
Study: 33051215
Drug: Phenylephrine 1%
Normalized name: Premier Value Phenylephrine 1% Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylephrine 1% and cyclopentolate 0.2% (treatment A)
Study: 33051215
Drug: Phenylephrine 0.5%
Normalized name: PHENYLEPHRINE 0.5%/MENTHOL NASAL SPRAY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylephrine 0.5% and cyclopentolate 0.1% (treatment B)
Study: 34794998
Drug: Patient-centred labels
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-centred labels (PCL) in low Rapid Estimate of Adult Literacy in Medicine scores
Study: 34794998
Drug: Standard labels
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard labels in low Rapid Estimate of Adult Literacy in Medicine scores
Study: 32455002
Drug: Cashew nut
Normalized name: Cashew nut
DrugBank: Cashew (DB10653)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cashew nut seed flour (daily intake for 24 weeks)
Study: 33853492
Drug: Discussed treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discussed treatment goals with doctors (450 respondents, 38.9%)
Study: 33853492
Drug: Not discussed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Not discussed treatment goals (287 respondents, 24.8%)
Study: 33853492
Drug: Anti-RANKL antibodies
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-RANKL antibodies
Study: 34215499
Drug: Aggressive intravenous
Normalized name: ZO SKIN HEALTH Aggressive Anti-Aging Program KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive intravenous hydration (20 ml/kg bolus followed by 3 ml/kg/hr)
Study: 34215499
Drug: Standard intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard intravenous hydration (10 ml/kg bolus followed by 1.5 ml/kg/hr)
Study: 34215499
Drug: Aggressive intravenous
Normalized name: ZO SKIN HEALTH Aggressive Anti-Aging Program KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive intravenous hydration in obese patients
Study: 34215499
Drug: Standard intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard intravenous hydration in obese patients
Study: 32558773
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of LAEF and LAmin volume
Study: 35440501
Drug: Dapagliflozin and
Normalized name: Dapagliflozin and metformin only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin and Eplerenone combination
Study: 34133509
Drug: Levetiracetam (titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levetiracetam (titrated from 20 mg/kg/day or 1,000 mg/day up to 60 mg/kg/day or 3,000 mg/day)
Study: 35232232
Drug: Scientific messaging
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scientific messaging endorsing the vaccine
Study: 35232232
Drug: Partisan messaging
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Partisan messaging endorsing the vaccine
Study: 34538401
Drug: Adaptive trial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adaptive trial design evaluating multiple agents in RCC
Study: 34283183
Drug: Canakinumab (450
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canakinumab (450 mg for body weight of 40‐<60 kg, 600 mg for 60‐80 kg, and 750 mg for >80 kg; n=227)
Study: 35724467
Drug: Etoricoxib (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoricoxib (60 mg, Day 1 to Day 8)
Study: 34006926
Drug: Anlotinib 12
Normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anlotinib 12 mg orally once daily for 14 days every 3 weeks
Study: 36346543
Drug: Pharmacist-led intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist-led intervention involving referral to treating physician for therapy intensification.
Study: 33576770
Drug: Higher augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher augmentation index
Study: 33694035
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (first CPAP application on titration night)
Study: 32676134
Drug: Vitamin B1
Normalized name: Vitamin B1
DrugBank: Monophosphothiamine (DB16023)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin B1 (300 mg tablet) and Gabapentin (300 mg capsules, 3 per day for 4 weeks)
Study: 36429394
Drug: Medical nutrition
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical nutrition therapy/counseling and nutrition education
Study: 34312823
Drug: Early albumin
Normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early albumin administration (within the initial 24 perioperative hours)
Study: 32460840
Drug: Combined group-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined group-based stabilization and skill-training (SST) intervention added to individual treatment
Study: 35351194
Drug: Subcutaneous tanezumab
Normalized name: tanezumab
DrugBank: Tanezumab (DB12335)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous tanezumab (2.5mg or 5mg every 8 weeks)
Study: 35351194
Drug: Oral NSAID
Normalized name: Ansaid Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral NSAID (twice daily naproxen, celecoxib, or diclofenac)
Study: 32192742
Drug: Continuous Transverse
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous Transverse Abdominal Plane (TAP) block with ropivacaine 0.375% 20 mL and ropivacaine 0.2%
Study: 32976869
Drug: Ralimetinib (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ralimetinib (100 mg/12 h) with chemoradiotherapy (RT 60 Gy in 30 fractions and TMZ 75 mg/m2/day)
Study: 32976869
Drug: Ralimetinib (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ralimetinib (200 mg/12 h)
Study: 32976869
Drug: Ralimetinib (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ralimetinib (300 mg/12 h)
Study: 32976869
Drug: Standard concurrent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard concurrent RT and TMZ
Study: 34620739
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin type A injection into the flexor digitorum brevis and quadratus plantae
Study: 34620739
Drug: Corticosteroid injection
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid injection (methylprednisolone) into the plantar fascia
Study: 36267745
Drug: H-VA (high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: H-VA (high-dose amoxicillin combined with VPZ): VPZ 20 mg b.i.d with amoxicillin 750 mg q.i.d for 7 days
Study: 36267745
Drug: L-VA (low-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-VA (low-dose amoxicillin combined with VPZ): VPZ 20 mg b.i.d plus amoxicillin 500 mg q.i.d for 7 days
Study: 36267745
Drug: VAC (amoxicillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: VAC (amoxicillin combined with VPZ and clarithromycin): VPZ 20 mg b.i.d plus amoxicillin 750 mg plus clarithromycin 500 mg for 7 days
Study: 36811812
Drug: Pridopidine 45
Normalized name: Pridopidine
DrugBank: Pridopidine (DB11947)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pridopidine 45 mg bid
Study: 35686460
Drug: Caffeine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (4 mg/kg) + Acute Intermittent Hypoxia (AIH; FIO2=0.10)
Study: 35686460
Drug: Caffeine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (4 mg/kg) + SHAM (FIO2=0.21)
Study: 33582533
Drug: Low glycemic
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low glycemic index diet therapy (LGIT) for 3 months along with ongoing antiepileptic drugs
Study: 33582533
Drug: Low glycemic
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low glycemic index diet therapy (LGIT)
Study: 34329580
Drug: Current approaches
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current approaches to risk stratification and treatment of polycythaemia vera
Study: 35076698
Drug: Convalescent plasma
Normalized name: Convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Convalescent plasma (CCP) treatment
Study: 35076698
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no CCP treatment)
Study: 33219473
Drug: Diagnostic-driven therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diagnostic-driven therapy
Study: 33219473
Drug: ANC <
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ANC < 0.1 × 10^9/L
Study: 33219473
Drug: ANC ≥
Normalized name: Absolute Neutrophil Count
Approvals — FDA: no, EMA: no, PMDA: no
Description: ANC ≥ 0.1 × 10^9/L
Study: 32890282
Drug: On-treatment mean
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: On-treatment mean SBP
Study: 35487708
Drug: Medicines at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medicines at Transition Intervention (MaTI)
Study: 33892217
Drug: ACT-guided treatment
Normalized name: ACT-101
DrugBank: ACT-101 (DB17000)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACT-guided treatment
Study: 35410433
Drug: Lumbrokinase plus
Normalized name: lumbrokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumbrokinase plus aspirin
Study: 34233378
Drug: 595-nm pulsed
Normalized name: NM-004
DrugBank: NM-004 (DB18066)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 595-nm pulsed dye laser (PDL) treatment with oxymetazoline cream
Study: 34233378
Drug: oxymetazoline cream
Normalized name: oxymetazoline Topical Cream
DrugBank: Oxymetazoline (DB00935)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oxymetazoline cream alone
Study: 35429351
Drug: Mechanical preparation+SE-FS
Normalized name: Selenomethionine Se-75
DrugBank: Selenomethionine Se-75 (DB09400)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mechanical preparation+SE-FS
Study: 32576228
Drug: 250 mL/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mL/day soy milk plus routine treatments
Study: 32576228
Drug: Routine treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatments only
Study: 32530412
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment with an early warning system for serum creatinine rise, immediate specialist consultation, and issuance of a patient kidney passport.
Study: 32530412
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment (intervention group)
Study: 36356999
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care treatment for low-risk BCCs.
Study: 36356999
Drug: Non-treatment arm
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-treatment arm with close monitoring using multispectral dermoscopy, reflectance confocal microscopy, and high-definition optical coherence tomography.
Study: 36356999
Drug: Non-treatment arm
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-treatment arm (control).
Study: 36356999
Drug: Treatment arm.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment arm.
Study: 32149427
Drug: VY‐AADC01 administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: VY‐AADC01 administration
Study: 32149427
Drug: Levopoda infusions
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levopoda infusions pre-VY‐AADC01
Study: 32149427
Drug: Levopoda infusions
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levopoda infusions post-VY‐AADC01
Study: 32735112
Drug: Ketone Ester
Normalized name: Ketonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketone Ester (KE) 65 g
Study: 32735112
Drug: Bicarbonate (BIC)
Normalized name: Potassium Bicarbonate
DrugBank: Potassium bicarbonate (DB11098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bicarbonate (BIC) 300 mg·kg‐1 body weight
Study: 35429955
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate (2 g) administered 1 hour before and 6 hours after ERCP
Study: 35429955
Drug: Placebo (normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (normal saline) administered 1 hour before and 6 hours after ERCP
Study: 35429955
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate (2 g) in high risk patients
Study: 35472497
Drug: 40 mm
Normalized name: Loving Comfort Knee High 30-40 mmHg Beige L
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mm Hg INP treatment
Study: 35472497
Drug: 10 mm
Normalized name: potassium 10 MMOL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mm Hg INP treatment (sham control)
Study: 32955174
Drug: Control therapy
Normalized name: Benzoyl Peroxide;Salicylic Acid;Vitamin E 8%; 2%; 5% Topical application Kit [INOVA 8/2 ACNE CONTROL THERAPY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control therapy (physician's choice of enzalutamide or abiraterone plus prednisone)
Study: 33504345
Drug: Co-therapy group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-therapy group (DMARDs plus glucocorticoids)
Study: 33176960
Drug: Locking plate
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Locking plate (group L, n = 45)
Study: 34739974
Drug: Follicular Phase
Normalized name: Follicular hormone
DrugBank: Estrone (DB00655)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Follicular Phase (FP) intervention: quit date set 6-8 days post onset of menses, nicotine replacement therapy transdermal patch for 4 weeks, telephone-based counseling for 6 weeks
Study: 34739974
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of Care (SC): no menstrual timing of quit date, nicotine replacement therapy transdermal patch for 4 weeks, telephone-based counseling for 6 weeks
Study: 35123461
Drug: Duloxetine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine treatment for 8 weeks
Study: 33861440
Drug: Curcumin nanomicelles
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin nanomicelles (80 mg/day) + Metformin (500 mg three times daily)
Study: 34471483
Drug: Proton-pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton-pump inhibitor treatment
Study: 34471483
Drug: Inhalation steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation steroids prescription
Study: 32185573
Drug: Topical tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical tranexamic acid (TXA) 2-g in 50 mL physiological saline solution
Study: 36029105
Drug: Recombinant RBD-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant RBD-based protein subunit vaccine (Noora vaccine) 80 µg
Study: 36029105
Drug: Recombinant RBD-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant RBD-based protein subunit vaccine (Noora vaccine) 120 µg
Study: 32991678
Drug: Azithromycin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (20 mg/kg/day) for 7 days
Study: 32991678
Drug: SXT (trimethoprim
Approvals — FDA: no, EMA: no, PMDA: no
Description: SXT (trimethoprim 10 mg/kg/day plus sulfamethoxazole 50 mg/kg/day) for 7 days